Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lorenz, D.
Right arrow Articles by Volkmann, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorenz, D.
Right arrow Articles by Volkmann, J.
Related Collections
Right arrow Tremor
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2006;66:1753-1755
© 2006 American Academy of Neurology
Brief Communications

No benefit of 3,4-diaminopyridine in essential tremor: A placebo-controlled crossover study

D. Lorenz, MD, K. Hagen, BSc, M. Ufer, MD, PhD, I. Cascorbi, MD, PhD, G. Deuschl, MD, PhD and J. Volkmann, MD, PhD

From the Department of Neurology (D.L., K.H., G.D., J.V.) and the Institute of Pharmacology (M.U., I.C.), University Hospital Schleswig-Holstein, Kiel, Germany.

Address correspondence and reprint requests to Dr. Jens Volkmann, Department of Neurology, Christian-Albrechts-University Kiel, Schittenhelmstr. 10, 24105 Kiel, Germany; e-mail: j.volkmann{at}neurologie.uni-kiel.de

3,4-Diaminopyridine (3,4-DAP) is a potassium channel blocker that has recently demonstrated an antioscillatory effect in humans by significantly reducing downbeat nystagmus. Based on the presumed role of intrinsic oscillations in the pathophysiology of essential tremor (ET), the authors conducted a double-blind, placebo-controlled crossover study assessing the antitremor effect of a single dose of 3,4-DAP in 19 patients with ET. They did not find any significant change in tremor severity as measured by clinical ratings or accelerometry.

Disclosure: The authors report no conflicts of interest.

Received October 6, 2005. Accepted in final form February 20, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.